PAVmed Inc. (PAVM) AI Stock Analysis

PAVmed Inc., based in New York, New York, operates as a medical device company developing healthcare technology solutions across the United States. Its product portfolio includes CarpX, a percutaneous device for carpal tunnel syndrome, EsoCheck for esophageal cell collection, and EsoGuard, an advanced DNA assay using bisulfite-converted next-generation sequencing technology for early detection of adenocarcinoma and Barrett's Esophagus. Its development pipeline features EsoCure for esophageal ablation, PortIO for intraosseous vascular access, NextFlo disposable infusion systems, the Veris cancer monitoring platform, NextVent single-use ventilators, FlexMO circulatory support cannulas, DisappEAR pediatric ear tubes, and Solys noninvasive glucose monitoring systems.

PAVmed generated $500,000 in revenue in FY2021 before dropping to $377,000 in FY2022. Revenue reached $2.5M in FY2023 and peaked at $3.0M in FY2024 with a gross margin of -101.6%. In FY2025, revenue dropped 97.6% to $71,000, while gross margin was -354.9% and operating margin was -30712.7%. Net income was $39.8M in FY2024 and $401,000 in FY2025, compared to net losses of -$50.3M, -$89.0M, and -$64.2M from FY2021 through FY2023. For the trailing twelve months ending June 30, 2026, revenue was $112,000, supported by quarterly revenue growth of 450.0% year-over-year, alongside an operating margin of -21278.8% and diluted EPS of -$14.20.

As of June 30, 2026, PAVmed held $3.8M in cash and short-term investments against total debt of $17.1M, yielding net debt of $13.3M. Total assets stood at $40.2M and shareholders' equity was $35.0M, representing a debt-to-equity ratio of 0.49 and a current ratio of 1.19. In FY2025, operating cash flow and free cash flow were both -$5.21B, influenced by R&D expenses of $4.49B. Capital expenditures were $31,000 in FY2025, and the company's share count decreased by 92.7% over the past five years.

With a market capitalization of $19.3M and an enterprise value of $49.5M, PAVmed trades at a price-to-sales multiple of 172.1x and an EV-to-revenue multiple of 442.1x. These multiples sit substantially above the median of its US-listed Healthcare peers, which carries a price-to-sales multiple of 4.1x and an EV-to-EBITDA multiple of 12.0x against PAVmed's 25.8x. Over the past year, PAVmed's stock fell 83.7%, trailing the S&P 500 (SPY) return of 16.8%, and is down 64.8% relative to its 200-day moving average.

Wall Street coverage includes 1 Strong Buy and 1 Buy rating, with no Hold, Sell, or Strong Sell ratings. The mean price target is $36.50, representing an upside of 1414.5% from the last close of $2.41. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$2.33 on revenue of $232,500. For the following fiscal year, 1 analyst projects revenue of $600,000 and an EPS of -$2.38. The company has beaten EPS expectations in 3 of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of PAVmed Inc. (PAVM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PAVM income statement, PAVM balance sheet, PAVM key metrics, PAVM analyst forecast, PAVM chart. See the PAVM stock overview for the latest quote and news.